Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Subscribe To Our Newsletter & Stay Updated
